Acquisition expands life sciences company’s medical tests portfolio
Life sciences company, Avacta Group, has acquired Coris Bioconcept SRL for an upfront cash consideration of £7.4m.
The deal - which complements Avacta's acquisition of Launch Diagnostics in 2022 - also includes an earnout based on future business performance, payable in cash, of up to £3m.
Coris, based in Gembloux, Belgium, and established in 1996, develops, manufactures and markets rapid diagnostic test kits, mainly lateral flow tests, for use by healthcare professionals.
